Insight

Improving Reporting Standards in Lung Cancer Trials

Lung Cancer/X

Dec 8, 2024, 04:24

Improving Reporting Standards in Lung Cancer Trials

Aakash Desai, Assistant Professor and Associate Director at UAB O’Neal Comprehensive Cancer Center, shared an article by William J. Phillips on LinkedIn:

“Improving Reporting Standards in Lung Cancer Trials.

A recent study published in International Association for the Study of Lung Cancer journal JTO (Articles in Press, Dec 4, 2024) highlights key gaps in reporting efficacy and toxicity in early-phase lung cancer trials:

88% of studies used subjective terms like “manageable” or “tolerable” (ISJET language) to describe toxicity.
Only 12% distinguished between Grade 1 and 2 adverse events (AEs), despite the growing relevance of chronic treatments.
These findings call for more objective and transparent reporting practices to align with modern oncology care needs. Better standards can lead to clearer data interpretation, benefiting researchers, clinicians, and patients alike.

The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.

Authors: William J. Phillips, et al.

Improving Reporting Standards in Lung Cancer Trials

More posts featuring Aakash Desai.

Aakash Desai cancer IASLC International Association for the Study of Lung Cancer JTO Lung cancer OncoDaily Oncology UAB O'Neal Comprehensive Cancer Center William J. Phillips

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research

Stella Kyriakides joins ESO as Co-Chair and Senior Lecturer in Cancer Policy to Guide the 2026–2028 Strategic Plan